

NAM PUBLICATIONS
(A Company Limited by Guarantee and Not Having a Share Capital)
UNAUDITED
TRUSTEES' REPORT AND FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2022

NAM PUBLICATIONS

(A Company Limited by Guarantee and Not Having a Share Capital)

CONTENTS

	Page
Reference and administrative details of the charity, its Trustees and advisers	1
Mission Statement and Introduction from NAM's Chair and Executive Director	2 - 3
Trustees' report	4 - 14
Independent examiner's report	15 - 16
Statement of financial activities	17
Balance sheet	18
Statement of cash flows	19
Notes to the financial statements	20 - 37

NAM PUBLICATIONS

(A Company Limited by Guarantee and Not Having a Share Capital)

**REFERENCE AND ADMINISTRATIVE DETAILS OF THE CHARITY, ITS TRUSTEES AND ADVISERS
FOR THE YEAR ENDED 31 DECEMBER 2022**

Trustees Tom Abell, Chair
Brian Cooper, Vice chair
Julia Reidy, Treasurer
Dr Sanjay Bhagani
Dr Julianne Lwanga
Jason Schroen
Mark Lewis (appointed 7 February 2023)
Iwan Roberts (appointed 7 February 2023)

Company registered number 02707596

Charity registered number 1011220

Registered office Cally Yard
439 Caledonian Road
London
N7 9BG

Company secretary Matthew Hodson

Independent examiner Marc Levy FCA

Accountants Blick Rothenberg Limited
Chartered Accountants
16 Great Queen Street
Covent Garden
London
WC2B 5AH

Bankers National Westminster Bank Plc
504 Brixton Road
London
SW9 8EB

Executive director Matthew Hodson

Managing Editor Roger Pebody

NAM PUBLICATIONS

(A Company Limited by Guarantee and Not Having a Share Capital)

MISSION STATEMENT AND INTRODUCTION FROM NAM'S CHAIR AND EXECUTIVE DIRECTOR FOR THE YEAR ENDED 31 DECEMBER 2022

Our Mission: NAM provides independent, accurate and accessible information about HIV.

Our Vision: A world where HIV is no longer a threat to health or happiness.

Message from NAM's Chair of the Board of Trustees


Over the past year we have continued to successfully navigate the post COVID landscape. We have made our presence felt nationally and internationally through our work, in our excellent conference and news reporting and have continued to build on the good work we initiated during COVID to develop new mechanisms to engage and inform those who can benefit from what we do.

Over the course of the past year we completed our skill mix review of the Board and have successfully recruited new Trustees to the organisation, however we recognise that there is still more to do to improve representation of all the communities we support.

We have also taken the first steps towards the delivery of our new strategy, as we look to broaden our impact and reach more communities nationally and internationally over the coming year.

As always, I want to thank everyone who has supported us over the course of the past year. In particular I wanted to personally thank all of our Trustees who continue to challenge, push and provide expert advice to make us more successful as an organisation.

I also want to thank all of our people who continue to work hard to take our mission forward and have responded so well to the myriad challenges that have presented themselves over the past few years. I also wanted to recognise the fantastic leadership of Matthew Hodson our Executive Director who has made this possible.

DocuSigned by:

B149BB086A2D4B8...
Tom Abell
Chair, NAM Publications

28-Sep-23 | 12:12 BST

NAM PUBLICATIONS

(A Company Limited by Guarantee and Not Having a Share Capital)

MISSION STATEMENT AND INTRODUCTION FROM NAM'S CHAIR AND EXECUTIVE DIRECTOR (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2022

Message from NAM's Executive Director

In 2022 NAM aidsmap celebrated 35 years as a charity.

The original National AIDS Manual, the HIV information resource which gave us our name, was compiled by volunteers at the London Lesbian and Gay Switchboard. They had been almost overwhelmed by the volume of calls prompted by their inclusion on the UK Government's 'Don't Die of Ignorance' leaflets.

The manual was a large ring-binder filled with yellow pages, providing details of the HIV support services that existed at the time and the most up to date information on how HIV is passed on. The options for HIV treatment and care were then extremely limited. HIV was still considered a death sentence.

In those 35 years since our founding the challenges that HIV presents have evolved. We now have effective treatment but one in four people who live with HIV globally are not able to access it. Our ability to prevent HIV transmission, through treatment and PrEP as well as traditional means, has never been better, and yet 1.5 million people acquired HIV in 2021. Women and marginalised communities continue to carry the heaviest burden of this disease, and the stigma that people with HIV face often intersects with other forms of prejudice.

NAM has evolved too. The adoption of a new strategy this year acknowledged our global reach and underlined our commitment to improving the lives of all who live with HIV, irrespective of borders. As nations, international agencies and organisations around the world make commitments to ending new HIV infections and deaths, we ensure that these efforts are supported through the provision of clear information to support policy and practice. Increasingly we respond to the diversity of need, experience and situation by presenting our resources in a variety of formats so as to reach broad audiences.

Clear, accurate and accessible information remain key to our ability to end new HIV infections, AIDS deaths and the harms perpetuated by this virus, including stigma. I am proud that 35 years after our founding, NAM aidsmap plays a leading role, globally, in the provision of essential HIV information.

DocuSigned by:

Matthew Hodson

13218886BDA547B...

Matthew Hodson
Executive Director, NAM Publications

Date: 28-Sep-23 | 14:05 BST

NAM PUBLICATIONS

(A Company Limited by Guarantee and Not Having a Share Capital)

TRUSTEES' REPORT

FOR THE YEAR ENDED 31 DECEMBER 2022

The trustees present their annual report together with the financial statements of the charity for the year 1 January 2022 to 31 December 2022. The Annual report serves the purposes of both a trustees' report and a directors' report under company law. The trustees confirm that the Annual report and financial statements of the charitable company comply with the current statutory requirements, the requirements of the charitable company's governing document and the provisions of the Statement of Recommended Practice (SORP) applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS102) (effective 1 January 2019).

Since the charity qualifies as small under section 382 of the Companies Act 2006, the Strategic report required of medium and large companies under the Companies Act 2006 (Strategic Report and Directors' Report) Regulations 2013 has been omitted.

In this report and elsewhere NAM Publications may sometimes be referred to by the abbreviated form, NAM, or with reference to one of its principle resources, NAM aidsmap.

Objectives and activities

a. Objectives and activities in 2022

Throughout 2022, the charity's objective, and its principal activity, continued to be the relief of sickness, hardship and distress among people with AIDS, HIV and related diseases and conditions. Since 2020 we have sought to ensure that people with HIV were equipped to deal with the emerging challenges posed by COVID-19 and, in 2022, an outbreak of what was initially called monkeypox, since renamed mpox, which affected many people already living with HIV. NAM also aims to advance the education of the public, including people working with those suffering from, or at risk of being affected by, such diseases and conditions.

There are no significant restrictions in the way the charity can operate and there have been no updates to the articles of the charity. Internal policies have been updated to reflect changes in relevant legislation and to equip the charity in the current environment.

The charity's mission, adopted at the beginning of 2022, is to provide independent, accurate and accessible information about HIV. Our vision is of a world where HIV is no longer a threat to health or happiness. The charity aims to create and disseminate information resources rooted in the experience of those most affected, enabling individuals and communities to take action and control in responding to HIV and AIDS.

NAM's main area of activity is the production and dissemination of accurate and reliable information about HIV in a variety of formats to meet the needs of diverse audiences.

NAM's main beneficiaries are:

- People living with HIV,
- People at risk of or affected by HIV; and
- People working in HIV, associated health conditions or with communities that have high HIV prevalence (including clinicians and other healthcare workers, researchers, prevention and public health specialists, policymakers, community advocates, activists and service providers).

In setting objectives and planning for activities, the trustees have given due consideration to general guidance published by the Charity Commission relating to public benefit, including the guidance 'Public benefit: running a charity (PB2)'

NAM PUBLICATIONS

(A Company Limited by Guarantee and Not Having a Share Capital)

TRUSTEES' REPORT (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2022

Achievements and performance

a. Achievements and performance in 2022

People who are informed, equipped and empowered are able to make better choices to support their own health. As the world emerged from the COVID pandemic, there was evidence that some of the progress made globally in diagnosing, treating and preventing HIV had been challenged, with programmes and research halted, hampered and delayed. The need for clear, reliable and accessible information for people with HIV remained.

Mpox, formerly known as monkeypox, which had been endemic in many countries with high HIV prevalence for decades, emerged as a health threat for gay and bisexual men in Western countries. People with HIV accounted for a disproportionate number of infections and, if not virally suppressed, suffering more severe or life-threatening illness.

Mpox illustrated, as COVID had before, that medical progress in treating and preventing HIV can still be derailed by new and emerging threats. As with COVID, NAM responded rapidly to this new threat, providing information for people living with HIV, winning plaudits for our response.

The aidsmap site remains the spine of our information provision but we have utilised and developed our skills to deliver workshops and a range of digital media projects online, through our own websites, social media and other platforms. In this way, in addition to the millions of visits to the aidsmap website, we also provided vital information about HIV and AIDS to millions of people on other platforms and in person.

aidsmap

The aidsmap site is NAM's primary means of providing information to our audiences around the world. Over the year we continued to develop the site to make the content more accessible to wider audiences, particularly through optimisation for handheld devices.

Aidsmap's page views in 2022 were higher than in any previous year, breaching over 3 million page views in Q3 alone, also breaking the record for most views in a quarter that had held since 2016.

Our urgent news stories on mpox were the most popular news stories of the year. The most popular information pages looked at estimated HIV risk for different exposure routes, the variation in window periods for different HIV tests and life expectancy for people living with HIV.

The aidsmap site recorded visits by people from 244 regions or countries, with the United States, South Africa, the United Kingdom, India, Kenya, Canada, the Philippines, Nigeria and Australia being the countries that accounted for the highest numbers, reflecting the global reach of our resources.

Bulletins

Our bulletins get information directly to the people who need news and information about HIV.

aidsmap news - provides treatment news particularly targeted and appropriate for healthcare providers and others professionally involved with HIV. Bulletins signpost in depth content on the site, helping healthcare providers deliver a better experience of care for people living with HIV. The aidsmap news bulletin now has 44,975 subscribers.

HIV Update - provides clear, accessible information particularly targeted and appropriate for people living with HIV. The HIV update bulletin now has 34,553 subscribers.

The Eurobulletin – a quarterly bulletin which provides information about policies, programmes, standards, guidance, evidence and research, and emerging issues in sexual and reproductive healthcare, HIV treatment and care, prevention and sexual health promotion. The Eurobulletin has 796 subscribers.

NAM PUBLICATIONS

(A Company Limited by Guarantee and Not Having a Share Capital)

TRUSTEES' REPORT (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2022

Achievements and performance (continued)

Conference reporting

In 2022 NAM aidsmap reported from Conference on Retroviruses and Opportunistic Infections (CROI), the British HIV Association Conference, the EACS Standard of Care for HIV and Co-infections in Europe and HIV Glasgow. Once again we were the official scientific media partner for the AIDS Conference, organised by IAS, which this year took place in Montreal. As a benefit of our Emerging Voice programme for training new writers, aidsmap had more correspondents reporting from AIDS 2022 than from any previous conference. For the first time we were able to send a writer to report directly from INTEREST, a conference focused on HIV/AIDS in sub-Saharan African countries.

Our conference bulletins, which go out in a variety of languages, currently have 70,266 subscribers.

aidsmapLIVE

In 2021 NAM broadcast seven editions of the award-winning aidsmapLIVE, hosted by NAM team member Susan Cole.

These broadcasts are viewed around the world and the audience are able to interact with the panel via social media. Guests this year included Winnie Byanima, Executive Director of UNAIDS, Professor Linda-Gail Bekker from the Desmond Tutu Health Foundation, Dr Laura Waters of the British HIV Association, and celebrated activists such as Greg Owen, Winnie Ssanyu Sseruma, Angelina Namiba, Harun Tulunay.

The 2022 editions of the show focussed on:

- Decades of HIV
- HIV and your best health
- AIDS 2022 Conference highlights
- HIV and stigma
- HIV prevention
- Can we end HIV by 2030?
- World AIDS Day

All episodes of aidsmapLIVE remain available to view on YouTube and on the aidsmap site.

aidsmapCHAT

aidsmapCHAT returned for a 5th season of six episodes. Hosted by NAM's Susan Cole and Matthew Hodson, the show features a diverse range of international community experts, policy-makers, politicians, researchers and clinicians as guests.

Guests in 2022 included Professor Kevin Fenton, the Public Health Regional Director for London who has the responsibility to deliver England's HIV Action Plan; Dr Claire Dewsnap, President of the British Association for Sexual Health and HIV; Dr Michael Brady, National Advisor for LGBT Health, trans writer, Juno Roche and Prevention Access's Bruce Richman.

aidsmapWOMEN

Originally commissioned for three episodes in 2020 / 2021, aidsmapWOMEN broadcast an additional episode in October 2022, focusing on women's self empowerment against HIV stigma. Guests included Florence Eshalomi MP, from the All Party Parliamentary Group on HIV /AIDS.

NAM PUBLICATIONS

(A Company Limited by Guarantee and Not Having a Share Capital)

TRUSTEES' REPORT (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2022

Achievements and performance (continued)

HIV information videos

Aidsmap Information videos: NAM created five new information videos on 'Tips for looking after your mental health'; 'PEP'; 'Adherence tips'; 'PrEP options' and 'HIV treatment and weight gain'. Each of these videos have achieved thousands of views across social media platforms and continue to be shared.

Positive Champions: NAM, working in partnership with Africa Advocacy Foundation, produced 19 videos of people from African and other racially minoritised communities living with HIV talking about the benefits of testing, including testimonials delivered in Swahili, Shona and Portuguese. NAM was rewarded additional funds to extend this project into 2023.

GROWS project: NAM, working in partnership with the Sophia Forum, Positively UK and UCL Institute for Global Health produced five new videos for women living with HIV, growing older, wiser and stronger.

HIV Stigma Project: NAM, working in partnership with the 4M Network of Mentor Mothers produced three short videos and one longer video looking at tools for tackling the stigma experienced by Black women living with HIV.

Positive Fitness: NAM worked with the Fitness agency Smash Mind and Body and delivered a fitness information and online workout for people living with HIV.

NAM Patient Information Resources

NAM published new editions of the Taking Your HIV Treatment and HIV and Women, both resources being available in print and online versions available for members of NAM's Clinic Scheme. In addition, we updated the following Basics resources, (online only, but downloadable versions available on the portal): Taking drugs on time, Myths and facts, Having a baby, Undetectable viral load.

The addition of a new HIV Information Editor to NAM's fulltime team has increased our capacity for creating new information pages and reviewing and updating existing information.

Community Engagement

This project supports people across the UK to live well with HIV, by developing new and innovative ways of engaging people living with, or at high risk of acquiring HIV with information relating to treatment, support and prevention. Following the move to more remote working precipitated by COVID many of our community engagement sessions were delivered online and were able to reach more people than ever before.

Our Community Engagement programme works directly with people living with HIV all across the UK, with particular success in reaching people from BAME communities, and women.

HIV Lens

HIV Lens is an interactive online mapping tool that visualises the impact of HIV epidemic on communities across England. The site is a collaboration between NAM and Watipa with support from Gilead Sciences.

This website presents information about HIV services and statistical data on HIV prevalence, incidence, testing and key populations, drawn from Public Health England. Data are accessible at different geographic levels which users of the site may use to plan effectively, compare how they are doing in relation to other areas and improve their services or policies.

infohep

infohep provided news, conference reporting and bulletins relating to hepatitis, primarily through the infohep website. These news stories and bulletins provided accessible and reliable information, advancing awareness of viral hepatitis, and increase knowledge of the condition enabling people to make more informed choices about treatment and care.

NAM PUBLICATIONS

(A Company Limited by Guarantee and Not Having a Share Capital)

**TRUSTEES' REPORT (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2022**

Achievements and performance (continued)

infohep (continued)

The infohep project began as a result of the high prevalence of HIV/HCV coinfection. With the advent of an effective cure for HCV infection the need for this service was reduced. The grant that NAM aidsmap received for infohep from Gilead was reduced, meaning that it was no longer feasible to deliver the project within the income raised to support it and so the decision was taken to bring the work to a controlled end, following reporting from the 2022 Liver Society Conference, archiving the information.

Emerging Voices

As part of our strategic commitment to ensuring that we reflect the diversity of our service users NAM created a mentoring programme to support new writers, particularly from communities that are underrepresented in scientific reporting. Emerging Voices gives new writers the opportunity to gain experience and develop their skills in a professional and supportive environment, providing them with paid opportunities to develop their skills and support people living with HIV.

The programme has brought new talent into the editorial team and a greater diversity of region and experience, reflecting the global epidemic. Several writers who came to NAM via the Emerging Voices programme are now regular freelance contributors to the site. The programme has contributed to NAM's strategic aim to reflect the diversity of our current and potential service users.

Social Media

Social media platforms, including Facebook, Twitter, Instagram, YouTube and WhatsApp play an ever-growing part of the way that people access and engage with information. aidsmap's news stories are always shared on the major platforms, and our digital projects, such as aidsmapLIVE and aidsmapCHAT, use Facebook and Twitter as their primary platforms.

In 2022 we refreshed the look of our Instagram profile and saw an increase in followers and engagement. NAM's use of social media and a range of digital platforms supports our strategic goals of utilising new platforms for delivering information, increasing NAM's public profile and being pro-active in providing information.

NAM aidsmap in the news

NAM's expertise was utilised throughout the year by specialist and mainstream media to provide context or insight to stories about HIV, COVID and mpox. Increasing NAM aidsmap's profile was a part of the 2017-2021 strategy, in order to increase awareness of the information services that we offer.

NAM PUBLICATIONS

(A Company Limited by Guarantee and Not Having a Share Capital)

TRUSTEES' REPORT (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2022

Achievements and performance (continued)

Future plans

At the beginning of 2022 NAM's Trustees adopted a new strategy, which refined NAM's mission and articulated for the first time NAM's vision and principles.

This strategy is intended to take NAM through to 2025.

Our Mission:

NAM provides independent, accurate and accessible information about HIV.

Our Vision:

A world where HIV is no longer a threat to health or happiness.

Our principles

Independent, accurate and accessible information is vital in the fight against HIV and AIDS.
Knowledge empowers and equips people to manage their health.
Knowledge enables advocates, campaigners and communities to take action on health.
The information we provide should help our audiences effect change in their own lives, their work or their communities.
Reducing HIV stigma removes barriers to testing and treatment.
Social inequalities must be addressed to deliver health equality.
We strive to serve individuals, communities and providers across the world, recognising that needs and culture differ.

Our audiences:

People living with HIV.
People at risk of or affected by HIV.
People working in HIV, associated health conditions or with communities that have high HIV prevalence (*including clinicians and other healthcare workers, researchers, prevention and public health specialists, policymakers, community advocates, activists and service providers*).

The ability to treat and prevent HIV is progressing rapidly.

NAM will continue to provide scientifically accurate information on prevention, treatment and cure, with a focus on emerging issues and new technologies.

Many international agencies, nations and organisations have committed to end new HIV infections and AIDS deaths by 2030.

NAM will support efforts to meet these targets through the provision of clear and accurate information to inform policy and practice.

NAM PUBLICATIONS

(A Company Limited by Guarantee and Not Having a Share Capital)

**TRUSTEES' REPORT (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2022**

Achievements and performance (continued)

The HIV epidemic is not over until it is over in all regions and communities.

NAM will deliver relevant HIV information to populations with high need, seeking to work in collaboration with local individuals and organisations.

HIV stigma creates barriers to testing and treatment and also impacts upon the emotional health of people living with HIV.

NAM will proactively challenge stigma through the creation of accessible resources highlighting, for example, the impact of HIV treatment on life-expectancy and transmission.

COVID and other health concerns create ongoing challenges for people living with HIV.

NAM will address the information needs of people living with HIV about COVID and other health concerns.

HIV affects diverse communities.

NAM will respond to the diversity of need, experience and situation of those who may benefit from our work by presenting information in a variety of formats and on multiple platforms to reach broad audiences.

The needs and experience of people with HIV intersect with other inequalities and inequities.

NAM's work will be informed by the understanding that needs are often intersectional and we will seek to empower those who are marginalised.

Financial review

a. Going concern

The trustees have considered the charity's cash flow forecast for the period ahead and are confident given the cash flow forecast and the charity's unrestricted funds that the charity remains viable over at least 12 months. Accordingly, the trustees have continued to adopt the going concern basis in the preparation of the accounts.

b. Reserves policy

The charity continues to operate in an uncertain funding climate in which it is difficult to estimate whether and when grants, sales and consultancy income will be received, and it is not uncommon for payments to be unexpectedly delayed. Because of these uncertainties, the Trustees consider it is necessary for the charity to hold reserves to cover expenditure in the event of a shortfall of income. In a worst-case scenario of charitable income suffering a disastrous decline, it would be necessary to cease operations and the trustees hold reserves to enable an orderly winding up to take place.

To allow for the eventualities described above, it is the trustees' present policy to hold free unrestricted reserves (i.e. excluding designated and restricted reserves) of not less than six months' running costs. At 31 December 2022 free reserves stood at £672,627 which was equivalent to 81% of projected expenditure for 2023, which was well above the minimum level of the policy. The trustees considered it prudent to hold reserves at a level higher than that stated in the current reserves policy in view of the continued unstable charity funding climate and the organisation's reliance upon funding from a limited number of funders. The trustees recognise that reserves are now at high level in relation to the current reserves policy and will review the reserves policy in 2023 to reflect the potential risks to our income. The trustees will aim to bring the charity's reserves back into line with the new policy over the medium term by running an operating deficit if required. It should be noted that the holding of significant levels of free reserves has enabled the charity to continue to serve its beneficiaries.

NAM PUBLICATIONS

(A Company Limited by Guarantee and Not Having a Share Capital)

TRUSTEES' REPORT (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2022

c. Financial performance review

The Statement of Financial Activities shows a reduction to unrestricted funds of £2,456.

The deficit was smaller than expected. Some budget plans that would have drawn on our unrestricted funds have been delayed until 2023. In addition, a number of projects with restricted funds that we had anticipated rolling into early 2023 we were able to complete in 2022, so fully utilising those funds. The net result being a lower operating deficit.

Total income for 2022 at £764,449 was £32,899 higher than in 2021. Total expenditure increased by £89,092, mainly a result of higher activity on our HIV Lens and Positive Champions projects. We also increased the size of our staff editorial team to support the updating and revising of our website.

Our restricted funds stood at £123,072 at the end of the financial year and will support projects in 2023. As unrestricted funds stood at £672,627 the total funds of the charity were £795,699 at 31 December 2022.

NAM holds its surplus funds in deposit accounts of UK clearing banks.

NAM would like to thank all of our supporters over the year including:

- Compare the Cloud
- Gilead Sciences (Europe)
- Gilead Sciences (UK)
- James Tudor Foundation
- MSD
- Mercury Phoenix Trust
- North East London NHS CSU (Fast Track Cities)
- Royal Free London NHS Foundation Trust (Fast Track Cities)
- The National Lottery Community Fund (Awards for All)
- The National Lottery Community Fund (Health Equalities)
- Theratechnologies
- The Terrence Higgins Trust
- ViiV Healthcare UK
- Wandsworth Oasis

In addition to the donors above we would also like to thank all our individual donors.

Structure, governance and management

a. Structure, governance and management

NAM Publications is registered as a charitable company limited by guarantee. Throughout the year under review the company was ruled by, and complied with, its revised Articles of Association dated 7 February 2011.

NAM Publications is also registered as a charity with the Charity Commission.

NAM's Board of Trustees set the organisational strategy and entrust the Executive Director to operationalise it. The Executive Director reports to the trustees formally at Board meetings, held every other month and may also seek ad hoc advice if required.

The Executive Director directly line manages the Managing Editor, Business Manager, Website Editorial Manager, Community Engagement, Marketing and Membership Manager and Fundraising and Development Manager. The Managing Editor has line management responsibility for the HIV Information Editor. The Website Editorial Manager has line management responsibility for the Head of Design.

NAM PUBLICATIONS

(A Company Limited by Guarantee and Not Having a Share Capital)

TRUSTEES' REPORT (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2022

Structure, governance and management (continued)

b. Methods of appointment or election of trustees

NAM's Chair, Deputy Chair and Treasurer are elected by the trustees.

NAM's Chair, Dr Margaret Swain stood down at the Trustees' meeting in February 2022.

NAM's Deputy Chair, Tom Abell, was elected Chair in February 2022.

Brian Cooper was elected Deputy Chair in February 2022.

NAM's Treasurer, Julia Reidy, was elected Treasurer in October 2019.

Trustees are recruited whenever a gap or deficit occurs in any of the following areas that are essential to NAM's successful operation: employment, finance, information provision, income generation, governance & management, asset management, external relations, quality standards and strategic implementation. Trustee recruitment may also occur whenever an opportunity arises to appoint an individual with a special combination of applicable experience, knowledge or skills; or when there is a sudden fall in board membership.

c. Policies adopted for the induction and training of trustees

New trustees are first interviewed by representatives of the board and staff management team and invited to attend a trustees' meeting prior to appointment. Trustees are advised to engage with guidance for trustees provided by the Charity Commission. Should further training needs or appropriate opportunities arise these may be met from the organisation's dedicated training budget.

d. Risk management

The charity has a risk management strategy which comprises:

- a bi-monthly review of the risks the charity may face
- the establishment of systems and procedures to mitigate those risks that are identified by the review; and
- the implementation of measures designed to minimise any potential impact on the charity should those risks materialise.

The trustees believe that the greatest risk facing the charity remains concern over the ability to maintain sufficient levels of income to cover all of the charitable expenditure.

Continuing efforts to diversify funding sources have had limited success and so the board has maintained high levels of free reserves to ensure continuation of delivery.

Members' liability

The Members of the charity guarantee to contribute an amount not exceeding £1 to the assets of the charity in the event of winding up. None of the trustees has any beneficial interest in the company.

Reference and administrative details

Registered office: 439 Caledonian Rd, London N7 9BG

Principal office: 439 Caledonian Rd, London N7 9BG

Company limited by guarantee, registered in England & Wales, company number: 2707596

Registered charity number: 1011220

NAM PUBLICATIONS

(A Company Limited by Guarantee and Not Having a Share Capital)

**TRUSTEES' REPORT (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2022**

Trustees

The trustees, who are also the directors for the purpose of company law, and who served during the year and since the year end were as follows:

Dr Margaret Swain	Chair since 5 Dec 2017 Stood down as Chair on 1 February 2022 and as a Trustee on 4 October 2022 Initially appointed 11 December 2012 Last re-appointed 2 February 2021
Tom Abell	Appointed Deputy Chair 3 December 2019 Re-appointed as Trustee 1 February 2022 Elected Chair on 1 February 2022
Julia Reidy	Appointed Treasurer 6 June 2019 Re-appointed 1 February 2022
Dr Sanjay Bhagani	Appointed 15 December 2015 Re-appointed 1 February 2022
Brian Cooper	Appointed 22 March 1999 Re-appointed 2 February 2021 Appointed Vice Chair 1 February 2022
Duncan Jarvies	Appointed 4 October 2016 Resigned 12 April 2022
Julianne Lwanga	Appointed 15 December 2017 Re-appointed 2 February 2021
Jason Schroen	Appointed 12 April 2017 Re-appointed 2 February 2021
Mark Lewis	Appointed 7 February 2023
Iwan Roberts	Appointed 7 February 2023

NAM PUBLICATIONS

(A Company Limited by Guarantee and Not Having a Share Capital)

TRUSTEES' REPORT (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2022

Statement of trustees' responsibilities

The trustees (who are also the directors of the charity for the purposes of company law) are responsible for preparing the Trustees' report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

Company law requires the trustees to prepare financial statements for each financial year. Under company law, the trustees must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the charity and of its incoming resources and application of resources, including its income and expenditure, for that period. In preparing these financial statements, the trustees are required to:


- select suitable accounting policies and then apply them consistently;
- observe the methods and principles of the Charities SORP (FRS 102);
- make judgments and accounting estimates that are reasonable and prudent;
- state whether applicable UK Accounting Standards (FRS 102) have been followed, subject to any material departures disclosed and explained in the financial statements;
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charity will continue in business.

The trustees are responsible for keeping adequate accounting records that are sufficient to show and explain the charity's transactions and disclose with reasonable accuracy at any time the financial position of the charity and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Small companies exemption

In preparing this report, the Trustees have taken advantage of the small companies exemptions provided by section 415A of the Companies Act 2006.

Approved by order of the members of the board of trustees and signed on their behalf by:

DocuSigned by:

B1498B086A2D4B8...
Tom Abell
Chair

Date: 28-Sep-23 | 12:12 BST

NAM PUBLICATIONS

(A Company Limited by Guarantee and Not Having a Share Capital)

INDEPENDENT EXAMINER'S REPORT FOR THE YEAR ENDED 31 DECEMBER 2022

Independent examiner's report to the trustees of NAM Publications ('the charity')

I report to the charity trustees on my examination of the accounts of the charity for the year ended 31 December 2022 which are set out on pages 17 to 37.

Responsibilities and basis of report

As the charity trustees of the company (and also its directors for the purposes of company law) you are responsible for the preparation of the accounts in accordance with the requirements of the Companies Act 2006 ('the 2006 Act').

Having satisfied myself that the accounts of the charity are not required to be audited under Part 16 of the 2006 Act and are eligible for independent examination, I report in respect of my examination of the charity's accounts carried out under section 145 of the Charities Act 2011 ('the 2011 Act'). In carrying out my examination I have followed the Directions given by the Charity Commission under section 145(5)(b) of the 2011 Act.

Independent examiner's statement

Since the charity's gross income exceeded £250,000 your examiner must be a member of a body listed in section 145 of the 2011 Act. I confirm that I am qualified to undertake the examination because I am a member of the ICAEW, which is one of the listed bodies.

I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe:

1. accounting records were not kept in respect of the charity as required by section 386 of the 2006 Act; or
2. the accounts do not accord with those records; or
3. the accounts do not comply with the accounting requirements of section 396 of the 2006 Act other than any requirement that the accounts give a 'true and fair' view which is not a matter considered as part of an independent examination; or
4. the accounts have not been prepared in accordance with the methods and principles of the Statement of Recommended Practice for accounting and reporting by charities applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102).

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.


NAM PUBLICATIONS

(A Company Limited by Guarantee and Not Having a Share Capital)

**INDEPENDENT EXAMINER'S REPORT (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2022**

Independent examiner's statement (continued)

This report is made solely to the charity's trustees, as a body, in accordance with Part 4 of the Charities (Accounts and Reports) Regulations 2008. My work has been undertaken so that I might state to the charity's trustees those matters I am required to state to them in an Independent examiner's report and for no other purpose. To the fullest extent permitted by law, I do not accept or assume responsibility to anyone other than the and the charity's trustees as a body, for my work or for this report.

DocuSigned by:

2FC62EAEFBDF41C...

Signed:

Dated: 28-Sep-23 | 15:38 BST

Marc Levy FCA (ICAEW)

Blick Rothenberg Limited

Chartered Accountants

16 Great Queen Street

Covent Garden

London

WC2B 5AH

NAM PUBLICATIONS**(A Company Limited by Guarantee and Not Having a Share Capital)****STATEMENT OF FINANCIAL ACTIVITIES (INCORPORATING INCOME AND EXPENDITURE ACCOUNT)
FOR THE YEAR ENDED 31 DECEMBER 2022**

	Note	Unrestricted funds 2022 £	Restricted funds 2022 £	Total funds 2022 £	Total funds 2021 £
Income from:					
Donations and legacies	3	68,304	-	68,304	54,327
Charitable activities	4	123,417	570,851	694,268	676,623
Investments	5	1,547	-	1,547	76
Other income	6	330	-	330	524
Total income		193,598	570,851	764,449	731,550
Expenditure on:					
Raising funds	7	1,069	-	1,069	1,065
Charitable activities	8	194,985	550,695	745,680	656,592
Total expenditure		196,054	550,695	746,749	657,657
Net movement in funds		(2,456)	20,156	17,700	73,893
Reconciliation of funds:					
Total funds brought forward		675,083	102,916	777,999	704,106
Net movement in funds		(2,456)	20,156	17,700	73,893
Total funds carried forward		672,627	123,072	795,699	777,999

The Statement of financial activities includes all gains and losses recognised in the year.

The notes on pages 20 to 37 form part of these financial statements.

NAM PUBLICATIONS**(A Company Limited by Guarantee and Not Having a Share Capital)****BALANCE SHEET****FOR THE YEAR ENDED 31 DECEMBER 2022**

	Note	2022 £	2021 £
Fixed assets			
Tangible assets	13	9,655	11,856
		<u>9,655</u>	<u>11,856</u>
Current assets			
Debtors	14	178,714	49,693
Cash at bank and in hand		716,998	829,110
		<u>895,712</u>	<u>878,803</u>
Creditors: amounts falling due within one year	15	(109,668)	(112,660)
Net current assets		<u>786,044</u>	<u>766,143</u>
Total assets less current liabilities		<u>795,699</u>	<u>777,999</u>
Total net assets		<u>795,699</u>	<u>777,999</u>
Charity funds			
Restricted funds	19	123,072	102,916
Unrestricted funds	19	672,627	675,083
Total funds		<u>795,699</u>	<u>777,999</u>

The charity was entitled to exemption from audit under section 477 of the Companies Act 2006.


The members have not required the company to obtain an audit for the year in question in accordance with section 476 of Companies Act 2006.

The trustees acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and preparation of financial statements.

The financial statements have been prepared in accordance with the provisions applicable to entities subject to the small companies regime.

The financial statements were approved and authorised for issue by the trustees and signed on their behalf by:

DocuSigned by:



.....B149BB086A2D4B8:.....

Tom Abell

Chair

Date: 28-Sep-23 | 12:12 BST

The notes on pages 20 to 37 form part of these financial statements.

NAM PUBLICATIONS**(A Company Limited by Guarantee and Not Having a Share Capital)****STATEMENT OF CASH FLOWS
FOR THE YEAR ENDED 31 DECEMBER 2022**

	Note	2022 £	2021 £
Cash flows from operating activities			
Net cash (used in)/provided by operating activities	22	(112,705)	301,367
Cash flows from investing activities			
Interest received		1,547	76
Purchase of tangible fixed assets	13	(954)	(9,841)
Net cash provided by/(used in) investing activities		593	(9,765)
Cash flows from financing activities			
Net cash provided by financing activities		-	-
Change in cash and cash equivalents in the year		(112,112)	291,602
Cash and cash equivalents at the beginning of the year		829,110	537,508
Cash and cash equivalents at the end of the year	23	716,998	829,110

The notes on pages 20 to 37 form part of these financial statements

NAM PUBLICATIONS**(A Company Limited by Guarantee and Not Having a Share Capital)****NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2022**

1. General information

NAM Publications is a charitable company limited by guarantee incorporated in England and Wales. The registered office is Cally Yard, 439 Caledonian Road, London, England, N7 9BG.

The financial statements are presented in Sterling (£), which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.

2. Accounting policies**2.1 Basis of preparation of financial statements**

The financial statements have been prepared in accordance with the Charities SORP (FRS 102) - Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019), the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Companies Act 2006.

NAM Publications meets the definition of a public benefit entity under FRS 102. Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy.

2.2 Going concern

The trustees have considered the charity's cash flow forecast for the period ahead. Notwithstanding the challenging funding environment influenced by factors such as the war in Ukraine and the cost of living crisis, the trustees believe that with careful management the charity has a reasonable expectation of having sufficient resources to continue in operation for the foreseeable future, this being 12 months from the date of approval of these financial statements. Accordingly, the trustees have continued to adopt the going concern basis in the preparation of the financial statements.

2.3 Income

Incoming resources are recognised in the period in which the charity is entitled to their receipt and the amount can be measured with reasonable certainty. Income is deferred only when the charity has to fulfil conditions before becoming entitled to it or where the donor or funder has specified that the income is to be used in a future accounting period.

The recognition of income from legacies is dependent on establishing entitlement, the probability of receipt and the ability to estimate with sufficient accuracy the amount receivable. Evidence of entitlement to a legacy exists when the charity has sufficient evidence that a gift has been left to them (through knowledge of the existence of a valid will and the death of the benefactor) and the executor is satisfied that the property in question will not be required to satisfy claims in the estate. Receipt of a legacy must be recognised when it is probable that it will be received and the fair value of the amount receivable, which will generally be the expected cash amount to be distributed to the charity, can be reliably measured.

Grants are included in the Statement of financial activities on a receivable basis. The balance of income received for specific purposes but not expended during the period is shown in the relevant funds on the Balance sheet. Where income is received in advance of entitlement of receipt, its recognition is deferred and included in creditors as deferred income. Where entitlement occurs before income is received, the income is accrued.

On receipt, donated professional services and facilities are recognised on the basis of the value of the gift to the charity which is the amount it would have been willing to pay to obtain services or facilities of equivalent economic benefit on the open market; a corresponding amount is then recognised in expenditure in the period of receipt.

NAM PUBLICATIONS**(A Company Limited by Guarantee and Not Having a Share Capital)****NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2022****2. Accounting policies (continued)****2.3 Income (continued)**

Other income is recognised in the period in which it is receivable and to the extent the goods have been provided or on completion of the service.

Subscription income from publications is recognised evenly over the period to which the subscription relates.

Interest income is recognised when receivable and the amount can be measured reliably.

2.4 Expenditure

Expenditure is recognised once there is a legal or constructive obligation to transfer economic benefit to a third party, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably. Expenditure is classified under the following headings:

- Costs of raising funds
- Expenditure on charitable activities
- Other costs not dealt with in the preceding headings.

Support costs are those functions that assist the work of the charity but do not directly undertake charitable activities. Support costs include staff costs, information technology costs, establishment costs and governance costs. These costs have been allocated between costs of raising funds and expenditure on charitable activities on a basis consistent with the use of resources, e.g. staff costs by time spent and other costs by estimated usage.

Expenditure on raising funds includes all expenditure incurred by the charity to raise funds for its charitable purposes and includes costs of all fundraising activities events and non-charitable trading.

Expenditure on charitable activities is incurred on directly undertaking the activities which further the charity's objectives, as well as any associated support costs.

2.5 Tangible fixed assets and depreciation

Tangible fixed assets are initially recognised at cost. After recognition, under the cost model, tangible fixed assets are measured at cost less accumulated depreciation and any accumulated impairment losses. All costs incurred to bring a tangible fixed asset into its intended working condition should be included in the measurement of cost.

At each reporting date the charity assesses whether there is any indication of impairment. If such indication exists, the recoverable amount of the asset is determined to be the higher of its fair value less costs to sell and its value in use. An impairment loss is recognised where the carrying amount exceeds the recoverable amount.

Depreciation is charged so as to allocate the cost of tangible fixed assets less their residual value over their estimated useful lives, through varying methods.

Depreciation is provided on the following basis:

Plant and machinery	-	25%	reducing balance
Fixtures and fittings	-	15%	on cost

Gains and losses on disposals are determined by comparing the proceeds with the carrying amount and are recognised in the Statement of financial activities.

NAM PUBLICATIONS**(A Company Limited by Guarantee and Not Having a Share Capital)****NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2022**

2. Accounting policies (continued)**2.6 Cash at bank and in hand**

Cash at bank and in hand includes cash and short-term highly liquid investments with a short maturity of three months or less from the date of acquisition or opening of the deposit or similar account.

2.7 Financial instruments

The charity has elected to apply Sections 11 and 12 of FRS 102 in respect of financial instruments.

Financial assets and financial liabilities are recognised when the charity becomes party to the contractual provisions of the instrument.

Financial liabilities are classified according to the substance of the contractual arrangements entered into.

The charity's policies for its major classes of financial assets and financial liabilities are set out below.

Financial assets

Basic financial assets, including trade and other debtors and cash and bank balances are initially recognised at transaction price, unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest for a similar debt instrument. Financing transactions are those in which payment is deferred beyond normal business terms or is financed at a rate of interest that is not a market rate.

Such assets are subsequently carried at amortised cost using the effective interest method, less any impairment.

Financial liabilities

Basic financial liabilities, including trade and other creditors are initially recognised at transaction price, unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest for a similar debt instrument. Financing transactions are those in which payment is deferred beyond normal business terms or is financed at a rate of interest that is not a market rate.

Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.

Impairment of financial assets

Financial assets measured at cost and amortised cost are assessed at the end of each reporting period for objective evidence of impairment. If objective evidence of impairment is found, an impairment loss is recognised in the profit and loss account.

For financial assets measured at cost less impairment, the impairment loss is measured as the difference between the asset's carrying amount and the best estimate of the amount the company would receive for the asset if it were to be sold at the reporting date.

For financial assets measured at amortised cost, the impairment loss is measured as the difference between the asset's carrying amount and the present value of estimated cash flows discounted at the asset's original effective interest rate. If the financial asset has a variable interest rate, the discount rate for measuring any impairment loss is the current effective interest rate determined under the contract.

NAM PUBLICATIONS**(A Company Limited by Guarantee and Not Having a Share Capital)****NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2022**

2. Accounting policies (continued)**Financial instruments (continued)**

If there is a decrease in the impairment loss arising from an event occurring after the impairment was recognised, the impairment is reversed. The reversal is such that the current carrying amount does not exceed what the carrying amount would have been had the impairment not previously been recognised. The impairment reversal is recognised in the statement of financial activities.

Derecognition of financial assets and financial liabilities

Financial assets are derecognised when (a) the contractual rights to the cash flows from the asset expire or are settled, or (b) substantially all the risks and rewards of the ownership of the asset are transferred to another party or (c) despite having retained some significant risks and rewards of ownership, control of the asset has been transferred to another party who has the practical ability to unilaterally sell the asset to an unrelated third party without imposing additional restrictions.

Financial liabilities are derecognised when the liability is extinguished, that is when the contractual obligation is discharged, cancelled or expires.

Offsetting of financial assets and financial liabilities

Financial assets and liabilities are offset and the net amount reported in the balance sheet when there is an enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

2.8 Operating leases

Rentals paid under operating leases are charged to the Statement of financial activities on a straight-line basis over the lease term.

2.9 Employee benefits

The cost of any unused holiday entitlement is recognised in the period in which the employee's services are received.

Termination benefits are recognised immediately as an expense when the charity is demonstrably committed to terminate the employment of an employee or to provide termination benefits.

2.10 Retirement benefits

The charity operates a defined contribution pension scheme for all qualifying employees and contributes to the personal pension plans of certain employees. The assets of the schemes are held separately from those of the charity in independently administered funds.

2.11 Fund accounting

General funds are unrestricted funds which are available for use at the discretion of the trustees in furtherance of the general objectives of the charity and which have not been designated for other purposes.

Restricted funds are subject to specific conditions by donors as to how they may be used. The purposes, name or funder of the restricted funds are set out in the notes to the financial statements.

Investment income, gains and losses are allocated to the appropriate fund.

NAM PUBLICATIONS**(A Company Limited by Guarantee and Not Having a Share Capital)****NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2022****2. Accounting policies (continued)****2.12 Company status**

The company does not have a share capital and the liability of its members is limited by guarantee to a maximum of £1 each.

The company satisfies the requirements of Section 60(1) of the Companies Act 2006 and having made a statutory declaration to this effect is exempt from using the word 'Limited' in its name.

3. Income from donations and legacies

	Unrestricted funds 2022 £	Total funds 2022 £	Total funds 2021 £
Donations	45,560	45,560	44,327
Legacies	4,044	4,044	10,000
Donated facilities	18,700	18,700	-
Total 2022	<u>68,304</u>	<u>68,304</u>	<u>54,327</u>
Total 2021	<u>54,327</u>	<u>54,327</u>	

4. Income from charitable activities

	Unrestricted funds 2022 £	Restricted funds 2022 £	Total funds 2022 £	Total funds 2021 £
Provision of HIV treatment information	93,492	411,253	504,745	446,275
Provision of information on viral hepatitis	2,640	10,000	12,640	34,903
Provision of information on HIV testing, transmission and prevention of HIV	-	71,802	71,802	53,686
Provision of social and non-clinical information on HIV	27,285	77,796	105,081	141,759
Total 2022	<u>123,417</u>	<u>570,851</u>	<u>694,268</u>	<u>676,623</u>
Total 2021	<u>172,695</u>	<u>503,928</u>	<u>676,623</u>	

NAM PUBLICATIONS**(A Company Limited by Guarantee and Not Having a Share Capital)****NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2022****5. Investment income**

	Unrestricted funds 2022 £	Total funds 2022 £	Total funds 2021 £
Interest receivable	1,547	1,547	76
	<u>76</u>	<u>76</u>	
Total 2021	<u>76</u>	<u>76</u>	

6. Other incoming resources

	Unrestricted funds 2022 £	Total funds 2022 £	Total funds 2021 £
Royalty income	330	330	524
	<u>524</u>	<u>524</u>	
Total 2021	<u>524</u>	<u>524</u>	

7. Expenditure on raising funds**Costs of raising voluntary income**

	Unrestricted funds 2022 £	Total funds 2022 £	Total funds 2021 £
Direct costs	1,069	1,069	1,065
	<u>1,065</u>	<u>1,065</u>	
Total 2021	<u>1,065</u>	<u>1,065</u>	

NAM PUBLICATIONS**(A Company Limited by Guarantee and Not Having a Share Capital)****NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2022****8. Analysis of expenditure on charitable activities****Summary by fund type**

	Unrestricted funds 2022 £	Restricted funds 2022 £	Total 2022 £	Total 2021 £
Provision of HIV treatment information	168,903	375,687	544,590	472,582
Provision of information on viral hepatitis	-	13,267	13,267	22,946
Provision of information on HIV testing, transmission and prevention of HIV	21,504	63,118	84,622	92,616
Provision of social and non-clinical information on HIV	4,578	98,623	103,201	68,448
Total 2022	<u>194,985</u>	<u>550,695</u>	<u>745,680</u>	<u>656,592</u>
Total 2021	<u>159,374</u>	<u>497,218</u>	<u>656,592</u>	

9. Analysis of expenditure by activities

	Activities undertaken directly 2022 £	Support costs 2022 £	Total funds 2022 £	Total funds 2021 £
Provision of HIV treatment information	503,798	40,792	544,590	472,582
Provision of information on viral hepatitis	12,836	431	13,267	22,946
Provision of information on HIV testing, transmission and prevention of HIV	73,946	10,676	84,622	92,616
Provision of social and non-clinical information on HIV	94,841	8,360	103,201	68,448
Total 2022	<u>685,421</u>	<u>60,259</u>	<u>745,680</u>	<u>656,592</u>
Total 2021	<u>602,656</u>	<u>53,936</u>	<u>656,592</u>	

NAM PUBLICATIONS**(A Company Limited by Guarantee and Not Having a Share Capital)****NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2022****9. Analysis of expenditure by activities (continued)****Analysis of direct costs**

	Provision of HIV treatment information 2022 £	Provision of information on viral hepatitis 2022 £	Provision of information on HIV testing, transmission and prevention of HIV 2022 £	Provision of social and non-clinical information on HIV 2022 £	Total funds 2022 £	Total funds 2021 £
Staff	240,211	2,686	66,119	52,167	361,183	335,258
Subcontractors and consultant writers	125,243	10,150	150	36,806	172,349	158,621
Printing, distribution and storage of resources	7,913	-	-	-	7,913	5,882
Translators	11,659	-	-	-	11,659	28,220
Establishment and depreciation	18,145	-	1,790	604	20,539	4,840
Recruitment and training	2,482	-	674	531	3,687	788
IT Webhosting and support	5,479	-	1,491	1,177	8,147	8,256
Administration	16,164	-	3,722	3,556	23,442	13,187
Other	66,610	-	-	-	66,610	47,284
Travel and subsistence	8,925	-	-	-	8,925	320
Marketing	967	-	-	-	967	-
	503,798	12,836	73,946	94,841	685,421	602,656
Total 2021	433,890	22,645	80,862	65,259	602,656	

NAM PUBLICATIONS**(A Company Limited by Guarantee and Not Having a Share Capital)****NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2022****9. Analysis of expenditure by activities (continued)****Analysis of support costs**

	Provision of HIV treatment information 2022 £	Provision of information on viral hepatitis 2022 £	Provision of information on HIV testing, transmission and prevention of HIV 2022 £	Provision of social and non-clinical information on HIV 2022 £	Total funds 2022 £	Total funds 2021 £
Staff	35,814	401	9,857	7,776	53,848	50,194
Establishment	2,667	4	183	83	2,937	792
IT	770	9	212	167	1,158	1,354
Miscellaneous	1,541	17	424	334	2,316	1,596
	<u>40,792</u>	<u>431</u>	<u>10,676</u>	<u>8,360</u>	<u>60,259</u>	<u>53,936</u>
Total 2021	<u>38,692</u>	<u>301</u>	<u>11,754</u>	<u>3,189</u>	<u>53,936</u>	

10. Trustees' remuneration and expenses

During the year, no trustees received any remuneration or other benefits (2021 - £NIL).

During the year ended 31 December 2022, no trustee expenses have been incurred (2021 - £NIL).

11. Staff costs

	2022	2021
	£	£
Wages and salaries	357,173	334,212
Social security costs	36,530	31,456
Other pension costs	21,328	19,784
	<u>415,031</u>	<u>385,452</u>

NAM PUBLICATIONS**(A Company Limited by Guarantee and Not Having a Share Capital)****NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2022****11. Staff costs (continued)**

The average number of persons employed by the charity during the year was as follows:

	2022 No.	2021 No.
Office and administration staff	3	3
Production staff	6	5
	<u>9</u>	<u>8</u>

The number of employees whose employee benefits (excluding employer pension costs) exceeded £60,000 was:

	2022 No.	2021 No.
In the band £60,001 - £70,000	1	1

Contributions totalling £4,042 (2021: £3,928) were made to defined contribution pension schemes on behalf of employees whose emoluments exceeds £60,000.

The total remuneration including the value of all monetary employee benefits for key management personnel was £133,824 (2021: £128,515).

12. Taxation

NAM Publications is a registered charity and therefore is not liable to income tax or corporation tax on income derived from its charitable activities, as it falls within the various exemptions available to registered charities.

NAM PUBLICATIONS**(A Company Limited by Guarantee and Not Having a Share Capital)****NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2022****13. Tangible fixed assets**

	Plant and machinery £	Fixtures and fittings £	Total £
Cost			
At 1 January 2022	25,992	1,250	27,242
Additions	954	-	954
At 31 December 2022	<u>26,946</u>	<u>1,250</u>	<u>28,196</u>
Depreciation			
At 1 January 2022	14,606	780	15,386
Charge for the year	3,084	71	3,155
At 31 December 2022	<u>17,690</u>	<u>851</u>	<u>18,541</u>
Net book value			
At 31 December 2022	<u><u>9,256</u></u>	<u><u>399</u></u>	<u><u>9,655</u></u>
At 31 December 2021	<u><u>11,386</u></u>	<u><u>470</u></u>	<u><u>11,856</u></u>

14. Debtors

	2022 £	2021 £
Due within one year		
Trade debtors	143,275	33,118
Other debtors	2,371	901
Prepayments and accrued income	33,068	15,674
	<u>178,714</u>	<u>49,693</u>

NAM PUBLICATIONS**(A Company Limited by Guarantee and Not Having a Share Capital)****NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2022****15. Creditors: amounts falling due within one year**

	2022	2021
	£	£
Trade creditors	49,008	45,483
Other taxation and social security	13,087	10,142
Other creditors	11,631	13,989
Accruals and deferred income	35,942	43,046
	109,668	112,660

16. Retirement benefit schemes

The charity operates a defined contribution pension scheme for all qualifying employees and contributes to the personal pension plans of certain employees. The assets of the schemes are held separately from those of the charity in independently administered funds.

Included in other creditors is an unpaid amount in respect of pension contributions of £4,250 (2021: £5,240).

The charge to the statement of financial activities in respect of defined contribution schemes was £21,328 (2021: £19,784).

17. Deferred income

	2022	2021
	£	£
Deferred income at 1 January 2022	19,196	79,003
Amounts received in the year	590,696	711,347
Amounts credited to SOFA	(694,268)	(676,623)
Movement in trade debtors	110,157	(94,531)
Deferred income at 31 December 2022	25,781	19,196

18. Independent examiner's remuneration

The independent examiner's remuneration amounts to an independent examiner fee of £6,000 (2021 - £5,500).

NAM PUBLICATIONS**(A Company Limited by Guarantee and Not Having a Share Capital)****NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2022****19. Statement of funds****Statement of funds - current year**

	Balance at 1 January 2022 £	Income £	Expenditure £	Balance at 31 December 2022 £
Unrestricted funds				
General Funds - all funds	675,083	193,598	(196,054)	672,627

	Balance at 1 January 2022 £	Income £	Expenditure £	Balance at 31 December 2022 £
Restricted funds				
1.Fast Track Cities London Improvement Collaborative Fund	15,500	54,000	(69,500)	-
2.Gilead Sciences Europe (News, bulletins and social media)	33,011	66,021	(53,326)	45,706
3.Gilead Sciences Europe (HIV Lens)	24,530	48,580	(69,407)	3,703
4.Gilead Sciences Europe (conferences)	10,295	15,783	(26,078)	-
5. Gilead UK and Ireland Fellowship Programme (aidsmapLIVES)	11,266	11,266	(22,532)	-
6. Gilead Sciences Europe (mpox)	-	26,950	(2,979)	23,971
7. MSD	1,912	31,178	(22,495)	10,595
8.National Lottery (Health & PoWER)	-	31,722	-	31,722
9. ViiV Healthcare (Changing lives)	-	153,975	(153,975)	-
10. ViiV Healthcare (Biomedical prevention options)	-	23,168	(23,168)	-
Others below £20,000	6,402	108,208	(107,235)	7,375
	102,916	570,851	(550,695)	123,072

	Balance at 1 January 2022 £	Income £	Expenditure £	Balance at 31 December 2022 £
Total of funds	777,999	764,449	(746,749)	795,699

NAM PUBLICATIONS**(A Company Limited by Guarantee and Not Having a Share Capital)****NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2022**

19. Statement of funds (continued)

Unrestricted funds are funds that the trustees are free to spend on any charitable activities.

Restricted funds relate to voluntary income received towards the charity's activities where the use is restricted by the conditions imposed by the grant providers. The majority of restricted income is spent in the same year that it is received.

A description of our material restricted funds is given below:

- 1. Fast Track Cities London Improvement Fund:** Grant towards early diagnosis and testing in Black African communities, training a group of Positive Champions, creating educational videos and conducting on the spot testing in a range of locations in south east London.
- 2. Gilead Sciences Europe:** Grant towards daily HIV prevention and treatment news stories, e-bulletins and creation of social media content.
- 3. Gilead Sciences Europe:** Grant towards HIV Lens an interactive online mapping tool that visualises the impact of the HIV epidemic on communities across England.
- 4. Gilead Sciences Europe:** Grant towards multi-lingual HIV conference news and e-bulletins for clinicians, healthcare staff, community-based organisations and patients.
- 5. Gilead UK and Ireland Fellowship Programme:** Grant towards a series of social media broadcast panel discussions sharing knowledge on important topics within HIV prevention, treatment and how to live well with HIV.
- 6. Gilead Sciences Europe:** Grant to help address a lack of resources tackling specific concerns around mpox for people living with and affected by HIV.
- 7. MSD:** Grant towards NAM aidsmap's PrEP in Europe Initiative.
- 8. The National Lottery Community Fund (Health & PoWER):** Grant towards a series of social media broadcasts in 2023 sharing information on health inequalities experienced by people of colour.
- 9. ViiV Healthcare (Changing Lives):** Grant towards NAM aidsmap's PrEP in Europe Initiative, multi-lingual HIV conference news coverage, aidsmapLIVE's broadcasts, Emerging Voices programme for new writers, and Sexual Health and HIV Policy EURObulletin.
- 10. ViiV Healthcare (Biomedical prevention options):** Grant towards increasing awareness of, and access to, HIV prevention technologies.

NAM PUBLICATIONS**(A Company Limited by Guarantee and Not Having a Share Capital)****NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2022****19. Statement of funds (continued)****Statement of funds - prior year**

	Balance at 1 January 2021 £	Income £	Expenditure £	Balance at 31 December 2021 £
Unrestricted funds				
General funds	607,900	227,622	(160,439)	675,083
	<hr/>	<hr/>	<hr/>	<hr/>
	Balance at 1 January 2021 £	Income £	Expenditure £	Balance at 31 December 2021 £
Restricted funds				
1.Fast Track Cities London Improvement Collaborative Fund	15,499	54,000	(53,999)	15,500
2.Gilead Sciences Europe (News, bulletins and social media)	16,505	66,021	(49,515)	33,011
3.Gilead Sciences UK (HIV Lens)	-	60,000	(35,470)	24,530
4.Gilead Sciences Europe (conferences)	-	41,176	(30,881)	10,295
5. MSD	-	28,536	(26,624)	1,912
6. ViiV Healthcare (Changing Lives)	-	150,104	(150,104)	-
Others below £20,000	64,202	104,091	(150,625)	17,668
	<hr/>	<hr/>	<hr/>	<hr/>
	96,206	503,928	(497,218)	102,916
	<hr/>	<hr/>	<hr/>	<hr/>
Total of funds	704,106	731,550	(657,657)	777,999
	<hr/> <hr/>	<hr/> <hr/>	<hr/> <hr/>	<hr/> <hr/>

NAM PUBLICATIONS**(A Company Limited by Guarantee and Not Having a Share Capital)****NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2022****20. Summary of funds****Summary of funds - current year**

	Balance at 1 January 2022 £	Income £	Expenditure £	Balance at 31 December 2022 £
General funds	675,083	193,598	(196,054)	672,627
Restricted funds	102,916	570,851	(550,695)	123,072
	<u>777,999</u>	<u>764,449</u>	<u>(746,749)</u>	<u>795,699</u>

Summary of funds - prior year

	Balance at 1 January 2021 £	Income £	Expenditure £	Balance at 31 December 2021 £
General funds	607,900	227,622	(160,439)	675,083
Restricted funds	96,206	503,928	(497,218)	102,916
	<u>704,106</u>	<u>731,550</u>	<u>(657,657)</u>	<u>777,999</u>

21. Analysis of net assets between funds**Analysis of net assets between funds - current year**

	Unrestricted funds 2022 £	Restricted funds 2022 £	Total funds 2022 £
Tangible fixed assets	9,655	-	9,655
Current assets	772,640	123,072	895,712
Creditors due within one year	(109,668)	-	(109,668)
Total	<u>672,627</u>	<u>123,072</u>	<u>795,699</u>

NAM PUBLICATIONS**(A Company Limited by Guarantee and Not Having a Share Capital)****NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2022****21. Analysis of net assets between funds (continued)****Analysis of net assets between funds - prior year**

	Unrestricted funds 2021 £	Restricted funds 2021 £	Total funds 2021 £
Tangible fixed assets	11,856	-	11,856
Current assets	775,887	102,916	878,803
Creditors due within one year	(112,660)	-	(112,660)
Total	<u>675,083</u>	<u>102,916</u>	<u>777,999</u>

22. Reconciliation of net movement in funds to net cash flow from operating activities

	2022 £	2021 £
Net income for the year (as per Statement of Financial Activities)	<u>17,700</u>	<u>73,893</u>
Adjustments for:		
Depreciation charges	3,155	3,879
Investment income	(1,547)	(76)
(Increase) / Decrease in debtors	(129,021)	248,141
(Decrease) / Increase in creditors	(9,577)	35,337
Increase / (Decrease) in deferred income	6,585	(59,807)
Net cash (used in)/provided by operating activities	<u>(112,705)</u>	<u>301,367</u>

23. Analysis of cash and cash equivalents

	2022 £	2021 £
Cash in hand	716,998	829,110
Total cash and cash equivalents	<u>716,998</u>	<u>829,110</u>

NAM PUBLICATIONS**(A Company Limited by Guarantee and Not Having a Share Capital)****NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2022****24. Analysis of changes in net debt**

	At 1 January 2022 £	Cash flows £	At 31 December 2022 £
Cash at bank and in hand	829,110	(112,112)	716,998
	<u>829,110</u>	<u>(112,112)</u>	<u>716,998</u>

25. Operating lease commitments

The charity had no commitments under non-cancellable operating leases at 31 December 2022.

26. Related party transactions

The charity has not entered into any related party transaction during the year, nor are there any outstanding balances owing between related parties and the charity at 31 December 2022.

Blick Rothenberg Limited
Palladium House
1-4 Argyll Street
London
W1F 7LD

NAM Publications
Cally Yard
439 Caledonian Road
London
N7 9BG

Date: 28-Sep-23 | 12:12 BST

Dear Sirs

NAM PUBLICATIONS

FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2022

This representation letter is provided in connection with your independent examination of the financial statements for the year ended 31 December 2022.

The following representations are made on the basis of enquiries of management and staff with relevant knowledge and experience such as we consider necessary in connection with your independent examination of the charity's financial statements for the year ended 31 December 2022. These enquiries have included inspection of supporting documentation where appropriate. All representations are made to the best of our knowledge and belief.

GENERAL

1. We have fulfilled our responsibilities as directors/trustees, as set out in the terms of your engagement letter under the Companies Act 2006 and Charities Act 2011 for preparing financial statements in accordance with the Companies Act 2006 and Charities Act 2011 and United Kingdom Generally Accepted Accounting Practice which you have drafted on our behalf, which give a true and fair view of the state of the charity's affairs as at 31 December 2022 and of its incoming resources and application of resources, including its income and expenditure for the year then ended, and for making accurate representations to you.
2. All the transactions undertaken by the charity have been properly reflected and recorded in the accounting records.
3. All accounting records have been made available to you for the purpose of your independent examination. All other records and related information, including minutes of all management and trustees' meetings, have been made available to you. We have provided you with unrestricted access to persons within the entity from whom you determined it necessary to obtain evidence.

4. We acknowledge our legal responsibilities regarding disclosure of information to you as independent examiners. Each director/trustee has taken all steps that he or she ought to have taken in order to make him or herself aware of any information relevant to the preparation of the financial statements and establish that you are aware of that information. As far as each director/trustee is aware, there is no information relevant to the independent examination of the financial statements of which you are unaware.
5. The financial statements are free of material misstatements, including omissions.

INTERNAL CONTROL AND FRAUD

6. We acknowledge our responsibility for the design, implementation and maintenance of internal control systems to prevent and detect fraud and error. We have disclosed to you the results of our risk assessment that the financial statements may be materially misstated as a result of fraud.
7. There have been no instances of known or suspected fraud affecting the charity involving management, employees who have a significant role in internal control or others that could have a material effect on the financial statements.
8. There have been no allegations of fraud or suspected fraud affecting the financial statements communicated by current or former employees, regulators or others.

ASSETS AND LIABILITIES

9. The charity has satisfactory title to all assets included in the financial statements and there are no charges on the charity's assets, except as disclosed in the notes to the financial statements.
10. We have no plans or intentions that may materially alter the carrying values or classification of assets and liabilities reported in the financial statements.

ACCOUNTING ESTIMATES

11. Significant assumptions used by us in making accounting estimates, including those measured at fair value, are reasonable.

LOANS AND ARRANGEMENTS

12. The charity has not granted any advances or credits to, or made guarantees on behalf of, directors/trustees.

LEGAL CLAIMS

13. We have disclosed to you all claims in connection with litigation that have been, or are expected to be, received and such matters, as appropriate, have been properly accounted for and disclosed in the financial statements.

LAWS AND REGULATIONS

14. There have been no known instances of non-compliance or suspected non-compliance with laws and regulations whose effects should be considered when preparing the financial statements.

RELATED PARTIES

15. We have disclosed to you the identity of the entity's related parties and all the related party relationships and transactions of which we are aware which require disclosure in order to comply with the requirements of applicable law and accounting standards.
16. All related party relationships and transactions have been appropriately accounted for and disclosed in the financial statements in accordance with the requirements of applicable law and accounting standards.
17. We confirm that the financial statements fairly reflect the position as regards the control of the charity and any ultimate controlling party.

SUBSEQUENT EVENTS

18. All events subsequent to the date of the financial statements which require adjustment or disclosure have been properly accounted for and disclosed.

GOING CONCERN

19. We believe that the charity's financial statements should be prepared on a going concern basis on the grounds that current and future sources of funding or support will be more than adequate for the charity's needs. We have considered a period of twelve months from the date of approval of the financial statements. We believe that no further disclosures relating to the charity's ability to continue as a going concern need to be made in the financial statements.


FUND ACCOUNTING

20. All grants, donations and other income, the receipt of which is subject to specific terms or conditions, have been notified to you. There have been no breaches of any terms or conditions in the application of such income.

21. Restricted funds are listed in Appendix 1.

Yours faithfully

For and on behalf of the Board of Directors/Trustees

DocuSigned by:

B149BB086A2D4B8...

Tom Abell

Chair

28-Sep-23 | 12:12 BST

Appendix 1

Restricted funds	Balance at 1 January 2022	Income	Expenditure	Balance at 31 December 2022
	£	£	£	£
Fast Track Cities London Improvement Collaborative Fund	15,500	54,000	(69,500)	-
Gilead Sciences Europe (News, bulletins and social media)	33,011	66,021	(53,326)	45,706
Gilead Sciences Europe (HIV Lens)	24,530	48,580	(69,407)	3,703
Gilead Sciences Europe (Conferences)	10,295	15,783	(26,078)	-
Gilead UK and Ireland Fellowship Programme (aidsmapLIVEs)	11,266	11,266	(22,532)	-
Gilead Sciences Europe (mpox)	-	26,950	(2,979)	23,971
MSD	1,912	31,178	(22,495)	10,595
National Lottery (Health & PoWER)	-	31,722	-	31,722
ViiV Healthcare (Changing Lives)	-	153,975	(153,975)	-
ViiV Healthcare (Biomedical prevention options)	-	23,168	(23,168)	-
Others below £20,000	6,402	108,208	(107,235)	7,375
	102,916	570,851	(550,695)	123,072

N3. 1

NAM Publications


Year End: 31 December 2022

Adjusting journal entries

Date: 01/01/2022 To 31/12/2022

Prepared by	Reviewed by	Final Review
RI Review	EQ Review	EQ Review Asst

Number	Date	Name	Account No	Reference	Debit	Credit	Net Income (Loss)	Amount Chg	Recurrence	Misstatement
Net Income (Loss) Before Adjustments							16,228			
A10	31/12/2022	HIV treatment info - UF - Establishm	1220D		15,317					
A10	31/12/2022	HIV treatment info - UF - support -	1260D		2,282					
A10	31/12/2022	Prevention of HIV - UF - Establishme	1420D		1,025					
A10	31/12/2022	Prevention of HIV - UF - support - E	1460D		77					
A10	31/12/2022	Prevention of HIV - UF - support - E	1460D							
A10	31/12/2022	Social and non-clin info - UF - supp	1560D			1				
A10	31/12/2022	Rent - Gift in Kind	1000.1			18,700				
Being the adjustment to recognise the Gift in Kind on the Rent.										Factual
					18,701	18,701	16,228	0		
A11	31/12/2022	Creditors control account	8010		1,472					
A11	31/12/2022	HIV treatment info - UF - Subcontrac	1220A			490				
A11	31/12/2022	Viral hepatitis - UF - Subcontractor	1320A			490				
A11	31/12/2022	Prevention of HIV - UF - Subcontract	1420A			492				
A11	31/12/2022	Social and non-clin info - UF - Subc	1520A			492				
Being the write off of the Keith alcorn payable										
					1,472	1,472	17,700	1,472		
					20,173	20,173	17,700	1,472		

DocuSigned by:

 B149BB086A2D4B8...

28-Sep-23 | 12:12 BST